{
    "clinical_study": {
        "@rank": "124191", 
        "arm_group": [
            {
                "arm_group_label": "Delta-9-THC", 
                "arm_group_type": "Active Comparator", 
                "description": "Delta-9-THC"
            }, 
            {
                "arm_group_label": "PF-04457845", 
                "arm_group_type": "Active Comparator", 
                "description": "Acquisition of conditioning Administration of drug Extinction of conditioning"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this double blind, randomized, controlled, proof-of-concept study is to test\n      the effects of cannabinoid receptor augmentation on the facilitation of fear conditioning.\n      On three days over not more than two weeks, subjects will be trained to associate cues with\n      two different stimuli, then this association will be extinguished. Cannabinoid receptor\n      stimulation will be accomplished both directly by administering the exogenous cannabinoid\n      \u03949-tetrahydrocannabinol (THC) and indirectly by harnessing the brain's capacity to\n      endocannabinoids through the administration of an enzyme (FAAH inhibitor) that prevents\n      degradation of anandamide. Subjects will receive placebo, \u03949-tetrahydrocannabinol (THC) or\n      the FAAH-inhibitor PF-04457845. Some details of this study have not been disclosed to\n      preserve the study design."
        }, 
        "brief_title": "Cannabinoid Augmentation of Fear Response in Humans", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Fear Conditioning", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must have used cannabis at least once in their lifetime\n\n        Exclusion Criteria:\n\n          -  Hearing problems\n\n          -  Psychiatric or mental problems"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01665573", 
            "org_study_id": "120303009906"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Delta-9-THC", 
                    "PF-04457845", 
                    "Placebo"
                ], 
                "description": "Acquisition of conditioning Administration of drug Extinction of conditioning", 
                "intervention_name": "Delta-9-THC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Delta-9-THC", 
                    "PF-04457845", 
                    "Placebo"
                ], 
                "description": "Acquisition of conditioning Administration of drug Extinction of conditioning", 
                "intervention_name": "PF-04457845", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Delta-9-THC", 
                    "PF-04457845", 
                    "Placebo"
                ], 
                "description": "Acquisition of conditioning Administration of placebo Extinction of conditioning", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Fear conditioning", 
            "Cannabinoids", 
            "Extinction learning"
        ], 
        "lastchanged_date": "April 1, 2014", 
        "location": {
            "contact": {
                "email": "lawrence.rispoli@yale.edu", 
                "last_name": "Lawrence V. Rispoli, B.A.", 
                "phone": "203-932-5711", 
                "phone_ext": "2526"
            }, 
            "facility": {
                "address": {
                    "city": "West Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06516"
                }, 
                "name": "VA Connecticut Healthcare System"
            }, 
            "investigator": {
                "last_name": "Mohini Ranganathan, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Cannabinoid Augmentation of Fear Response in Humans", 
        "overall_contact": {
            "email": "lawrence.rispoli@yale.edu", 
            "last_name": "Lawrence V Rispoli, BA", 
            "phone": "203-932-5711", 
            "phone_ext": "2526"
        }, 
        "overall_official": {
            "affiliation": "Yale University", 
            "last_name": "Mohini Ranganathan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Measure of anxiety", 
                "measure": "Startle Probe", 
                "safety_issue": "No", 
                "time_frame": "Test days #1, #2, and #3, on average a week"
            }, 
            {
                "description": "Measure of sympathetic autonomic activation", 
                "measure": "Galvanic skin response", 
                "safety_issue": "No", 
                "time_frame": "Test days #1, #2, and #3, on average a week"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01665573"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yale University", 
            "investigator_full_name": "Mohini Ranganathan", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Yale University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}